Pauric Bannigan, Intrepid Labs, explains how physics-informed machine learning aids formulation and why regulators still want experimental data.
News|Articles|April 1, 2005
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-04-01-2005
- Volume 17
- Issue 4
Nanostructured Lipid Carriers: A Novel Generation of Solid Lipid Drug Carriers
Nanostructured lipid carriers are a new type of delivery system offering improved performance in terms of drug loading and long-term stability with the ability to form highly concentrated dispersions...
Advertisement
Articles in this issue
over 21 years ago
Nanotechnology Applications for Drug Deliveryover 21 years ago
Nanotech Not Big Enough for Pharma?over 21 years ago
Protecting Intellectual Property Prior to Commercializationover 21 years ago
Ion Exchange Resinates — The Technology Behind the Mysteryover 21 years ago
Maintaining the Safety of EU Drugsover 21 years ago
Defining The BordersAdvertisement
Related to this article
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Pauric Bannigan, Intrepid Labs, explains where AI speeds formulation decisions, why data is the bottleneck, and how active learning trains models with far less data.
Stephanie Johnson, Pfizer, explains how off-platform triggers, single-owner risk registers, and traceable prior knowledge keep protein formulation programs on track.
Stephanie Johnson, Pfizer, discusses how platform formulations moved 2 Pfizer protein programs to IND in 8 months by redistributing, not removing risk.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
2
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
3
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
4
Formulation Risk Needs One Accountable Owner: AAPS PharmSci 360 2026
5